Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Apr 16, 2024
Data Byte
Neumora hold likely more of a setback for company than drug class
At least seven biopharmas have disclosed M4 programs for schizophrenia
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Dec 23, 2023
Deals
Persistence, creative combinations behind Karuna’s $14B exit
BMS acquires Karuna, brightening the spotlight on schizophrenia, muscarinic receptors and neurology
BioCentury | Oct 12, 2022
Finance
Oct. 11 Quick Takes: Large syndicate backs Neumora in $112M round
Plus Lilly, Nimbus in deal for AMPK activators, and updates from PureTech-Nektar, Albireo, Merck and more
BioCentury | Sep 6, 2022
Distillery Therapeutics
Targeting three thalamic circuits in Parkinson's disease
BioCentury | Aug 8, 2022
Product Development
Karuna’s Phase III schizophrenia success primes company for takeout
Results validate CEO Steven Paul’s ‘simple but elegant’ approach to improving xanomeline’s tolerability in schizophrenia patients
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | Jan 15, 2022
Discovery & Translation
HLA-independent TCRs with increased antigen sensitivity; plus Synthekine, Luminary and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 413